Everything seems to go right for Pharmacyte Biotech Inc (OTCMKTS:PMCB) at the moment. As per the reports, the company has decided to complete the minimum formalities needed to initiate clinical trials.
Insights On Matter:
Pharmacyte Biotech is one of the most sought after clinical stage biotechnology companies in today’s time. The primary focus of this company is to develop various high-end treatments for diabetes and cancer using Cell-in-a-Box; live-cell encapsulation technology.
In a recent statement, the company announced that all the genetically modified cells have been fully tested by it. These cells are required to initiate three clinical trials by Pharmacyte Biotech. The team of scientists is working on propagating these cells to develop the advanced cells necessary for executing the clinical trials in an effective manner.
Road So far:
While explaining the development of these cells, one of the spokesmen of the company said that all of these cells came from the characterized single-cell clone of all those cells that were previously used by the company. Pharmacyte Biotech keeps conducting various clinical trials from time to time. It successfully conducted clinical trials to find out the cure for pancreatic cancer lately. All the cells that were used in these trials were cloned and kept safe for the future usage. It has decided to use these cloned cells to develop the cells for the current trials.
In order to ensure the highest standards of product quality, Pharmacyte Biotech Inc (OTCMKTS:PMCB) has grown all the cells according to the current Good Manufacturing Practices. One of the trials at this company comprises of Phase 2b trial in which the pancreatic cancer treatment developed by Pharmacyte Biotech is compared with the best available chemotherapy for the pancreatic cancer in the market. It has prepared in the best possible way to conduct many such trials in the near future.